Sodium Oligomannate Capsules (GV-971) has been approved for treatment of mild to moderate
Alzheimer's disease and improving the cognitive function of patients. This study plans to
observe, in the clinical patients, the long-term efficacy and safety of GV-971, as well as
the changes in blood and gut microbiota biomarkers after treatment, to validate the mechanism
of action of GV-971, in order to better guide the rational use of drug in clinical practice.